Print

Intellikine, Inc., a Leading Developer of Small Molecule Drugs Targeting the PI3K/mTOR Pathway, Names Dr. Gregory Berk Chief Medical Officer  
7/12/2011 8:38:02 AM

LA JOLLA, Calif.--(BUSINESS WIRE)--Intellikine, Inc. announced today the appointment of Gregory I. Berk, M.D. as Chief Medical Officer. Prior to joining Intellikine, Dr. Berk served as Senior Vice President of Global Clinical Development at Celgene Corporation, where he was a key member of the Celgene-Abraxis Integration team during Celgene’s acquisition of Abraxis BioScience. Prior to Celgene, Dr. Berk was Senior Vice President of Global Clinical Development at Abraxis BioScience, where he was responsible for the company’s overall clinical strategy, including efforts to expand the indications for Abraxane® in lung cancer, pancreatic cancer and malignant melanoma.
//-->